JP2018528258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528258A5 JP2018528258A5 JP2018521475A JP2018521475A JP2018528258A5 JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5 JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- pharmaceutical composition
- organ
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| US62/192,269 | 2015-07-14 | ||
| US201562197966P | 2015-07-28 | 2015-07-28 | |
| US62/197,966 | 2015-07-28 | ||
| US201662277201P | 2016-01-11 | 2016-01-11 | |
| US62/277,201 | 2016-01-11 | ||
| PCT/US2016/042074 WO2017011544A1 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003152A Division JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528258A JP2018528258A (ja) | 2018-09-27 |
| JP2018528258A5 true JP2018528258A5 (https=) | 2019-08-15 |
| JP6826113B2 JP6826113B2 (ja) | 2021-02-03 |
Family
ID=57757587
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Active JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10874738B2 (https=) |
| EP (2) | EP3331548B1 (https=) |
| JP (4) | JP6826113B2 (https=) |
| KR (2) | KR20250099272A (https=) |
| CN (2) | CN114671952A (https=) |
| AU (3) | AU2016294417B2 (https=) |
| CL (1) | CL2018000103A1 (https=) |
| CO (1) | CO2018001363A2 (https=) |
| CR (1) | CR20180097A (https=) |
| DO (1) | DOP2018000018A (https=) |
| EA (1) | EA201890297A1 (https=) |
| EC (1) | ECSP18009949A (https=) |
| GT (1) | GT201800018A (https=) |
| HK (1) | HK1249735A1 (https=) |
| IL (3) | IL256800B2 (https=) |
| MX (2) | MX2018000548A (https=) |
| MY (2) | MY196991A (https=) |
| PE (1) | PE20180741A1 (https=) |
| PH (1) | PH12018500098A1 (https=) |
| SG (1) | SG10201913431QA (https=) |
| TN (1) | TN2018000021A1 (https=) |
| WO (1) | WO2017011544A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL256800B2 (en) * | 2015-07-14 | 2023-04-01 | Immunext Inc | An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy |
| WO2017089618A1 (en) | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| CA3096222A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| EP3856246A4 (en) * | 2018-09-24 | 2022-07-20 | Janssen Biotech, Inc. | METHOD FOR ENSURING SAFE ADMINISTRATION OF ANTI-CD154 ANTIBODY |
| CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
| US20220185785A1 (en) * | 2019-04-12 | 2022-06-16 | TONIX Pharmaceuticals Holding Corp | Inhibitors of cd40-cd154 binding |
| CN114746120B (zh) * | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| CN113488170B (zh) * | 2021-07-02 | 2023-07-25 | 温州医科大学 | 急性前葡萄膜炎复发风险预测模型构建方法及相关设备 |
| EP4382537A4 (en) * | 2021-07-30 | 2025-07-23 | Seoul Nat Univ R&Db Foundation | ANTI-CD154 ANTIBODY AND ITS USE |
| WO2023008982A1 (ko) * | 2021-07-30 | 2023-02-02 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| CN121358768A (zh) | 2023-04-28 | 2026-01-16 | 信达生物制药(苏州)有限公司 | 抗cd40l抗体及其在人自身免疫疾病治疗的应用 |
| IL324827A (en) * | 2023-05-22 | 2026-01-01 | Genzyme Corp | Treating multiple sclerosis using anti-CD40L antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0721469T3 (da) | 1993-09-02 | 2000-05-01 | Dartmouth College | Anti-gp39-antistoffer og anvendelse deraf |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6444018B1 (en) | 1998-06-25 | 2002-09-03 | Xerox Corporation | Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| MXPA03003144A (es) * | 2000-10-13 | 2004-12-06 | Biogen Inc | Anticuerpos humanizados anti-lt-??-r. |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| EP1639014B1 (en) * | 2003-06-13 | 2010-09-22 | Biogen Idec MA Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| PT2125894T (pt) * | 2007-03-22 | 2019-02-27 | Biogen Ma Inc | Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações |
| US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| CA2832281C (en) * | 2011-04-04 | 2019-11-05 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| IL256800B2 (en) * | 2015-07-14 | 2023-04-01 | Immunext Inc | An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy |
-
2016
- 2016-07-13 IL IL256800A patent/IL256800B2/en unknown
- 2016-07-13 MY MYPI2018700104A patent/MY196991A/en unknown
- 2016-07-13 EP EP16825103.1A patent/EP3331548B1/en active Active
- 2016-07-13 MX MX2018000548A patent/MX2018000548A/es unknown
- 2016-07-13 JP JP2018521475A patent/JP6826113B2/ja active Active
- 2016-07-13 EP EP26164394.4A patent/EP4732909A2/en active Pending
- 2016-07-13 IL IL310460A patent/IL310460A/en unknown
- 2016-07-13 WO PCT/US2016/042074 patent/WO2017011544A1/en not_active Ceased
- 2016-07-13 CR CR20180097A patent/CR20180097A/es unknown
- 2016-07-13 CN CN202210146798.5A patent/CN114671952A/zh active Pending
- 2016-07-13 AU AU2016294417A patent/AU2016294417B2/en active Active
- 2016-07-13 PE PE2018000072A patent/PE20180741A1/es unknown
- 2016-07-13 SG SG10201913431QA patent/SG10201913431QA/en unknown
- 2016-07-13 HK HK18109202.5A patent/HK1249735A1/zh unknown
- 2016-07-13 CN CN201680053004.3A patent/CN108135969B/zh active Active
- 2016-07-13 US US15/744,379 patent/US10874738B2/en active Active
- 2016-07-13 MY MYPI2020006781A patent/MY203911A/en unknown
- 2016-07-13 KR KR1020257020732A patent/KR20250099272A/ko active Pending
- 2016-07-13 EA EA201890297A patent/EA201890297A1/ru unknown
- 2016-07-13 TN TNP/2018/000021A patent/TN2018000021A1/en unknown
- 2016-07-13 IL IL297907A patent/IL297907B2/en unknown
- 2016-07-13 KR KR1020187004571A patent/KR102825142B1/ko active Active
-
2018
- 2018-01-11 PH PH12018500098A patent/PH12018500098A1/en unknown
- 2018-01-12 CL CL2018000103A patent/CL2018000103A1/es unknown
- 2018-01-12 MX MX2023014921A patent/MX2023014921A/es unknown
- 2018-01-12 DO DO2018000018A patent/DOP2018000018A/es unknown
- 2018-01-12 GT GT201800018A patent/GT201800018A/es unknown
- 2018-02-09 EC ECIEPI20189949A patent/ECSP18009949A/es unknown
- 2018-02-12 CO CONC2018/0001363A patent/CO2018001363A2/es unknown
-
2020
- 2020-11-23 US US17/101,139 patent/US11596689B2/en active Active
-
2021
- 2021-01-13 JP JP2021003152A patent/JP2021063129A/ja active Pending
-
2022
- 2022-11-02 AU AU2022263520A patent/AU2022263520B2/en active Active
-
2023
- 2023-02-01 US US18/162,769 patent/US20240000929A1/en active Pending
- 2023-07-05 JP JP2023110414A patent/JP7605914B2/ja active Active
-
2024
- 2024-12-12 JP JP2024217195A patent/JP2025038055A/ja active Pending
-
2025
- 2025-09-05 AU AU2025226796A patent/AU2025226796A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528258A5 (https=) | ||
| US7169389B2 (en) | Human CD154 binding molecules and treatment methods | |
| TWI889694B (zh) | 介白素-2藥劑及其用途 | |
| JP7267921B2 (ja) | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 | |
| US20080227704A1 (en) | CXCL13 binding proteins | |
| TWI496790B (zh) | 介白素-１３結合蛋白質 | |
| AU2013206788B2 (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| AU2001248350A1 (en) | Antibodies to human CD154 | |
| JP2014516945A5 (https=) | ||
| CN108367075A (zh) | 4-1bb结合蛋白及其用途 | |
| TW201031421A (en) | IL-1 binding proteins | |
| JP2020073499A (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| JP2011520898A5 (https=) | ||
| JP2020521452A5 (https=) | ||
| JP2016527187A5 (https=) | ||
| JP2013500721A5 (https=) | ||
| JP2015504419A (ja) | Ｔ細胞反応の選択的阻害のための抗体および方法 | |
| BR112013012396A2 (pt) | anticorpos anti-ccl20 de neutralização | |
| Stirling et al. | Future treatments of allergic diseases and asthma | |
| JPWO2020208177A5 (https=) | ||
| JP2023514224A (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| TW202031685A (zh) | Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途 | |
| JPWO2020102739A5 (https=) | ||
| US20250034230A1 (en) | Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof | |
| JP2015533374A5 (https=) |